News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on ResMed.
RELATED STOCKHEAD STORIES
News
RBA to maintain historic low rates until at least 2024
Experts
ScoPo’s powerplays: Market hit by profit-taking, but healthcare outperforms
Experts
ScoPo’s powerplays: Bullish on mobile X-ray company Micro-X
News
ScoPo’s powerplays: Morgans’ healthcare picks for 2021
News
The best asset class in 2021 could be one that’s been ignored for ‘nearly a decade’
Experts
Scopo’s powerplays: Feeling bullish for end of 2020
Experts
Scopo’s Health Powerplays: Show me the (grant) money
News
What ASX investors should look for in a COVID-19 earnings season
Experts
Scopo’s powerplays: Strap yourselves in for some M&A
News
‘Dividend recession’ heading for the Australian market
Health & Biotech
COVID-19 adds $9bn to top four ASX health stocks
News
Kick Back: The 10 biggest stories you might have missed on Stockhead this week
Health & Biotech
Greens push for permanent telehealth funding
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Health & Biotech
We’re still here: investors keen on health despite market shun
Experts
Scopo’s health powerplays: Markets be crazy, buy the dip
Experts
